Halozyme Therapeutics Inc
Halozyme Therapeutics's GHG Emissions Data Preview
In 2024, Halozyme Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Halozyme Therapeutics has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature.  | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 2 | ||||
Location-Based | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature. | 0000000 | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0000000 | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 |
Verified Sources Behind Halozyme Therapeutics’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Halozyme Therapeutics’s data sources below and access millions more through our Disclosure Search.
Insights into Halozyme Therapeutics's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Halozyme Therapeutics amounted to 3,461.16 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Halozyme Therapeutics's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Halozyme Therapeutics's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Halozyme Therapeutics were 1,347.71 metric tons of CO₂ equivalent (tCO₂e).a
What are Halozyme Therapeutics's Scope 2 emissions?
In 2024, Halozyme Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 2,113.45 tCO₂e using the location-based method.a
What methodology does Halozyme Therapeutics use for Scope 2 reporting?
In 2024, Halozyme Therapeutics reported its Scope 2 emissions using the location-based method.a
Halozyme Therapeutics's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
Insights into Halozyme Therapeutics's Value Chain Emissions
In 2024, Halozyme Therapeutics reported 30.46 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Halozyme Therapeutics includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in , reflecting improved emissions accounting practices and greater transparency across the company's value chaina
Halozyme Therapeutics's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Halozyme Therapeutics's Scope 3 emissions?
In 2024, Halozyme Therapeutics reported total Scope 3 emissions of 30.46 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
What categories of Scope 3 emissions does Halozyme Therapeutics disclose?
In 2024, Halozyme Therapeutics reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Halozyme Therapeutics's Scope 3 emissions?
In 2024, the largest contributors to Halozyme Therapeutics's Scope 3 emissions were:a
- Upstream Leased Assets (Cat. 8): 30.46 tCO₂e (100%)
Halozyme Therapeutics's Scope 3 Emissions by Categories
Insights into Halozyme Therapeutics’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Halozyme Therapeutics reported Scope 1 greenhouse gas (GHG) emissions of 1,347.71 tCO₂e and total revenues of USD 1,015 millions. This translates into an emissions intensity of 1.33 tCO₂e per millions USD.a
Halozyme Therapeutics's Scope 1 Emissions Intensity Compared to Peers
How does Halozyme Therapeutics's GHG emissions intensity compare to its peers?
In 2024, Halozyme Therapeutics reported a Scope 1 emissions intensity of 1.33 tCO₂e per millions USD. Compared to the peer group median of 2.45, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
Where does Halozyme Therapeutics rank on GHG emissions intensity within its industry?
In 2024, Halozyme Therapeutics ranked 9 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Halozyme Therapeutics is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
Insights into Halozyme Therapeutics's Total Carbon Footprint
In 2024, Halozyme Therapeutics reported a total carbon footprint of 3,491.62 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions.a
The largest contributor to Halozyme Therapeutics's total carbon footprint was Scope 2 emissions, accounting for 60.53% of the company's total carbon footprint, followed by Scope 1 emissions at 38.6%.a